PF-562271 HCl: Precision FAK/Pyk2 Inhibitor Transforming Cancer Research

Understanding the Principle: PF-562271 HCl as a FAK/Pyk2 Inhibitor

The intricate signaling pathways governed by focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2) are central to cancer cell adhesion, migration, and survival. Disrupting these kinases offers a strategic avenue for tumor growth inhibition and metastasis suppression. PF-562271 HCl is a potent, ATP-competitive, and reversible focal adhesion kinase inhibitor, exhibiting an IC₅₀ of 1.5 nM for FAK and 14 nM for Pyk2, with a tenfold selectivity in favor of FAK. Its >100-fold selectivity over most other kinases (with minimal off-target CDK activity) makes it a gold-standard tool for targeted cancer research.

This compound's ability to inhibit FAK phosphorylation has been demonstrated in tumor-bearing mouse models, achieving an EC₅₀ of 93 ng/mL and resulting in robust tumor growth inhibition and metastasis suppression. By modulating the focal adhesion kinase signaling pathway, PF-562271 HCl enables researchers to study cancer progression, tumor microenvironment modulation, and anti-cancer drug development with unprecedented precision.

For more detailed product specifications and ordering information, see the PF-562271 HCl product page by APExBIO.

Step-by-Step Experimental Workflow and Protocol Enhancements

1. Compound Preparation

• Dissolve PF-562271 HCl in DMSO at ≥26.35 mg/mL. Gentle warming (≤37°C) can accelerate dissolution. Do not use water or ethanol as solvents, as the compound is insoluble in these.
• Prepare aliquots to minimize freeze-thaw cycles and store at -20°C. Use solutions promptly; avoid long-term storage in solution to maintain inhibitor stability.

2. In Vitro Assays

• Cell Proliferation and Migration Assays: Treat cancer cell lines (e.g., prostate, breast, or lung) with 0.1–10 μM PF-562271 HCl. Monitor phenotypic changes in adhesion, spreading, proliferation, and migration using live-cell imaging or endpoint assays (e.g., MTT, wound healing).
• FAK/Pyk2 Phosphorylation Inhibition: Harvest cells after 1–4 hours of treatment. Perform Western blotting for phosphorylated FAK (Y397) and Pyk2 (Y402) to confirm pathway inhibition. Quantify inhibition relative to untreated controls.
• Dose–Response Studies: Generate IC₅₀ curves across a range of concentrations (0.1–1000 nM) to validate compound potency in your specific cell model.

3. In Vivo Applications

• Tumor Xenograft Models: Administer PF-562271 HCl to tumor-bearing mice at doses established in preclinical literature (e.g., 25–50 mg/kg, orally or intraperitoneally). Monitor tumor volume, metastasis incidence, and FAK phosphorylation in tumor lysates.
• Tumor Microenvironment Studies: Examine immune cell infiltration, stromal remodeling, and angiogenesis via immunohistochemistry or flow cytometry, leveraging the inhibitor's impact on the tumor microenvironment.

Protocol Enhancement Tips

• Combine PF-562271 HCl with RNAi or CRISPR approaches for synergistic pathway dissection.
• Integrate time-course analyses to capture dynamic changes in signaling and cellular phenotypes.

Advanced Applications and Comparative Advantages

PF-562271 HCl's superior selectivity and nanomolar potency unlock advanced applications beyond standard kinase inhibition. For instance, in the context of prostate cancer, recent work by Song et al. (Cancer Letters, 2025) revealed the role of circRHOBTB3 in suppressing metastatic progression via transcriptional regulation. PF-562271 HCl enables researchers to experimentally validate the involvement of FAK/Pyk2 signaling in circRNA-mediated tumor suppression, dissecting the crosstalk between non-coding RNA, focal adhesion kinase activity, and metastatic behavior.

Compared to other FAK inhibitors, PF-562271 HCl offers:

• Robust, quantifiable inhibition of FAK phosphorylation (EC₅₀ of 93 ng/mL in vivo)
• Proven efficacy in both in vitro and in vivo models
• Minimal off-target kinase activity, supporting clean mechanistic studies
• Strong utility in modeling tumor microenvironment modulation and metastatic niche formation

This compound's strengths are further contextualized in recent literature. For example, the article "Dissecting Metastatic Mechanisms: Strategic Application of PF-562271 HCl" complements the present discussion by offering a deep dive into tumor-associated macrophage dynamics and metastatic niche formation, extending the utility of PF-562271 HCl beyond its canonical roles. Meanwhile, "PF-562271 HCl: Advanced FAK/Pyk2 Inhibitor for Precision Oncology" provides stepwise protocol optimization, serving as a practical companion to the advanced applications detailed here. Finally, "A Next-Generation Tool for FAK/Pyk2 Pathway Research" extends the conversation to small-molecule library design, highlighting PF-562271 HCl's role in drug discovery initiatives.

Troubleshooting and Optimization Tips

• Low Inhibitory Activity Detected: Confirm compound integrity (avoid repeated freeze-thaw cycles), verify DMSO stock concentration, and ensure rapid usage of freshly prepared solutions. Check for batch-to-batch variability with control assays.
• Cellular Toxicity: Titrate DMSO concentration (keep ≤0.1% v/v final) and perform vehicle control experiments. Use lower PF-562271 HCl concentrations and monitor off-target effects.
• Solubility Issues: Always dissolve in DMSO, applying gentle heat if needed. Avoid aqueous buffers for stock solutions. If precipitation occurs in culture, increase mixing or dilute stocks immediately before use.
• Variable In Vivo Response: Validate compound exposure (e.g., via LC-MS/MS), ensure proper administration routes, and monitor animal health parameters closely. Adjust dosing schedules based on pharmacokinetic readouts.
• Off-Target or Incomplete Pathway Blockade: Supplement with genetic knockdown (e.g., siRNA or CRISPR) or use orthogonal pathway inhibitors to confirm phenotype specificity.

For detailed troubleshooting strategies and protocol enhancements, refer to the comprehensive guide "ATP-Competitive FAK/Pyk2 Inhibitor for Cancer Research", which discusses robust anti-tumor and microenvironment modulation tools.

Future Outlook: PF-562271 HCl in Next-Generation Oncology

As the landscape of cancer research evolves, PF-562271 HCl is poised to remain a cornerstone for unraveling FAK/Pyk2 pathway dynamics, informing immunotherapy response, and driving next-generation therapeutic discovery. Its unparalleled selectivity and performance enable the nuanced study of tumor microenvironment modulation, metastatic niche formation, and the interplay between non-coding RNAs and kinase signaling—a research frontier underscored by the circRHOBTB3 findings in metastatic prostate cancer (Song et al., 2025).

Moreover, as small-molecule libraries expand and translational oncology pivots towards pathway-centric interventions, PF-562271 HCl will serve as both a mechanistic probe and a lead candidate for novel anti-cancer therapeutics. Researchers can expect continued innovation in combination strategies, biomarker-driven applications, and real-time pathway monitoring, underpinned by the trusted quality and scientific support of APExBIO.